CYTK250516P30000
- 0.59
- 0.000.00%
Cytokinetics Newsroom
Morgan Stanley Maintains Cytokinetics(CYTK.US) With Buy Rating, Cuts Target Price to $65
Express News | Cytokinetics Announces Four Upcoming Presentations at the European Society of Cardiology Heart Failure 2025 Congress
Cytokinetics Is Maintained at Overweight by Barclays
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $53 to $107
Express News | Cytokinetics, Inc. : Barclays Cuts Target Price to $53 From $55
Cytokinetics Receives Buy Rating Amid Positive Outlook for Aficamten and Strong Financial Position
Cytokinetics' Earnings Call: Balancing Progress and Challenges
Press Release: Cytokinetics to Hold Annual Meeting of Stockholders
Express News | Cytokinetics to Hold Annual Meeting of Stockholders
Cytokinetics Is Maintained at Outperform by RBC Capital
Cytokinetics Price Target Cut to $80.00/Share From $86.00 by Citigroup
Cytokinetics Analyst Ratings
RBC Trims Price Target on Cytokinetics to $80 From $82, Keeps Outperform, Speculative Risk
BofA Securities Maintains Cytokinetics(CYTK.US) With Hold Rating, Cuts Target Price to $45
Citi Maintains Cytokinetics(CYTK.US) With Buy Rating, Cuts Target Price to $80
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $120
Cytokinetics: Hold Rating Amid FDA Delays and Commercial Uncertainties
Earnings Call Summary | Cytokinetics(CYTK.US) Q1 2025 Earnings Conference
Cytokinetics Targets Aficamten Approval With Extended PDUFA Timeline and Growing Clinical Data
Cytokinetics Reports Q1 2025 Financials and Strategic Progress